Novel BCL-2 Inhibitor Combo Shows Enduring Responses in R/R Myeloma Subtype
Data from a phase 1b/2 trial show that sonrotoclax/dexamethasone appears to be well tolerated in a heavily pretreated multiple myeloma population.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Nivolumab/RT Improves Biochemical Recurrence Outcomes in Prostate Cancer
Phase 2 data support further evaluation of nivolumab plus standard radiotherapy in patients with Gleason grade 5 prostate cancer.
Advancing Glioblastoma Research Through a Phase 3 Niraparib Trial
Investigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.
Isatuximab Combo Yields MRD-Negative Responses in Transplant-Eligible NDMM
Nearly all patients in the per-protocol population of the MIDAS study achieved a very good partial response or better following study treatment.
Daratumumab Combo Yields MRD-Negative Status in Transplant-Ineligible NDMM
Phase 3 data support a daratumumab-based quadruplet as a new potential regimen in transplant-ineligible newly diagnosed multiple myeloma.
